CurrentUnitedHealthcarePolicy CS2024D0033AC

Xolair (omalizumab) provider-administered injections

UnitedHealthcare medical benefit drug policy for provider-administered Xolair (omalizumab) covering indications (moderate-severe persistent asthma, chronic urticaria, nasal polyps, IgE-mediated food allergy), clinical criteria for initial and reauthorization, dosing alignment with FDA labeling, provider prescribing specialties, and exclusions for combination biologic therapy. Does not apply in specified states where state-specific guidance exists.

Policy Summary

PayerUnitedHealthcare

PolicyXolair (omalizumab) provider-administered injections

Policy CodePolicy CS2024D0033AC

Change TypeAdded IgE-mediated food allergy; other content revised/removed

Effective DateAug 1, 2024

Next Review Date

Key ActionDocument required clinical criteria and physician attestation that self-administration is not appropriate where applicable; initial and reauthorization approvals limited to no more than 12 months.

POLICY UPDATE CHANGES

Added 'emergency treatment of allergic reactions, including anaphylaxis' to the list of unproven and not medically necessary indications.

Removed 'peanut allergy' from the list of unproven and not medically necessary indications.

Added IgE-mediated Food Allergy section (new to policy) with initial and continuation criteria for provider administration.

Removed language pertaining to maximum dosage requirements; refer to Medical Benefit Drug Policy titled Maximum Dosage and Frequency.

Updated Background, Clinical Evidence, FDA, and References sections to reflect current information.

Archived previous policy version CS2023D0033AB.

4Covered Indications (Asthma, Chronic Urticaria, Nasal Polyps, IgE-mediated Food Allergy)

30-1300 IU/mL

Coverage Summary

Scope: This UnitedHealthcare medical benefit drug policy covers provider‑administered Xolair (omalizumab) for indicated conditions including moderate to severe persistent allergic asthma, chronic idiopathic/chronic spontaneous urticaria (CIU/CSU), nasal polyps, and IgE‑mediated food allergy. The policy applies to healthcare professional administration (self‑administered Xolair is obtained under the pharmacy benefit) and does not apply in specified states where state‑specific guidance exists (see state exceptions).

Coverage stance: Xolair is covered with criteria as a provider‑administered injection when the indicated clinical criteria are met (diagnosis confirmation, diagnostic thresholds such as baseline total serum IgE for asthma, prior therapy trials, and documentation). Prescribing must align with specified specialty requirements (e.g., allergist/immunologist, pulmonologist, dermatologist, otolaryngologist as applicable), dosing must follow the FDA‑approved labeling, and initial and reauthorization approvals are limited to no more than 12 months. The policy also includes requirements for physician attestation when self‑administration is not appropriate and excludes combined use with certain biologic therapies.

Key policy thresholds

Baseline total serum IgE>= 30 IU/mL and <= 1,300 IU/mL

Age for IgE‑mediated food allergy>= 1 year

Asthma symptom control thresholdsACQ > 1.5 or ACT < 20 (defines poor control)

Authorization durationInitial and reauthorization approvals: no more than 12 months

Supervised initial/re‑initiation dosesAuthorization for 3 supervised doses when new to therapy or after >=6 months interruption

Initial Therapy Criteria

Continuation / Reauthorization Criteria

Unproven Indications & Exclusions

Unproven / Not medically necessary additions and removals: the policy revision explicitly added “emergency treatment of allergic reactions, including anaphylaxis” to the list of unproven and not medically necessary indications and removed “peanut allergy” from that unproven/not medically necessary list per the change log.

Contraindications and exclusions: the policy prohibits concurrent biologic therapy with anti‑IL‑4 agents (e.g., dupilumab), anti‑IL‑5 agents (e.g., mepolizumab, reslizumab, benralizumab), and TSLP inhibitors (e.g., tezepelumab). A history of hypersensitivity or anaphylaxis to Xolair or other agents is addressed as a reason for initial supervised administration or as a contraindication/precaution within the physician attestation requirements.

Applicable Codes

Applicable HCPCSHCPCS

J2357

Injection, omalizumab, 5 mg

Relevant ICD-10 Diagnoses referencedICD-10

J33.0	Polyp of the nasal cavity
J33.1	Polypoid sinus degeneration
J33.8	Other polyp of sinus
J33.9	Nasal polyp, unspecified
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation
J44.9	Chronic obstructive pulmonary disease, unspecified
J45.40	Moderate persistent asthma, uncomplicated
J45.41	Moderate persistent asthma with (acute) exacerbation
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation

1–10 of 20

1/2

Applicable Codes (header present — specific codes not listed in this Part 2 extract)mixed

No codes listed

Provider Actions & Billing Rules

Prior Authorization

Authorization required for provider-administered Xolair

Prior authorization is required for provider-administered Xolair (omalizumab). Initial and reauthorization requests must include documentation that clinical criteria are met and a physician attestation where applicable. Approvals will be limited to no more than 12 months.

Initial and reauthorization requests must include complete clinical documentation demonstrating all applicable indication-specific criteria are met.
Physician attestation required where noted in indication criteria (e.g., self-administration unsuitability).
Approvals limited to ≤ 12 months.

Documentation Required

Document baseline IgE and allergen sensitization

Document baseline immunologic testing and allergen sensitization where indicated to support the diagnosis and appropriateness of Xolair therapy.

Clinical Evidence

68%Peanut ≥600 mg response with Xolair vs placebo (68% vs 5%; diff 63%)

65%Peanut ≥1000 mg response with Xolair vs placebo (65% vs 0%; diff 65%)

24 wksSustained CIU/CSU effect with omalizumab 300 mg up to 24 weeks

NPS ≥5Nasal polyps trial entry requirement: bilateral NPS ≥5 with ≥2 in each nostril and weekly NCS >1 despite mometasone

Clinical evidence summary: randomized and controlled evidence supporting omalizumab includes the ICATA trial (inner‑city anti‑IgE therapy) demonstrating significant reductions in asthma symptoms and exacerbations in children/adolescents with persistent allergic asthma, the ASTERIA I trial showing that omalizumab 300 mg q4w reduced itch severity and symptom scores in H1‑antihistamine‑refractory CIU/CSU, and two randomized phase 3 nasal polyps trials showing efficacy of omalizumab as add‑on therapy to nasal corticosteroids with improvements in smell, post‑nasal drip, and runny nose.

Food allergy evidence: randomized trial data in peanut‑allergic pediatric patients showed markedly higher response rates with Xolair versus placebo for tolerating predefined peanut protein doses (e.g., ≥600 mg: Xolair 68% vs placebo 5%; ≥1000 mg: Xolair 65% vs placebo 0%). Real‑world and additional studies summarized in the background support overall safety and effectiveness across indications; pooled pediatric and observational data show improvements in control and reductions in exacerbations with an acceptable safety profile consistent with trial findings.

Background & Definitions

Background: Omalizumab is a recombinant anti‑IgE monoclonal antibody that binds circulating IgE and prevents IgE interaction with high‑affinity Fc receptors on effector cells, reducing mediator release and allergic responses. The FDA‑approved indications include moderate to severe persistent allergic asthma (ages ≥6 years), chronic idiopathic urticaria (age ≥12 years), nasal polyps (adults ≥18 years), and IgE‑mediated food allergy (age ≥1 year) with use and monitoring precautions for anaphylaxis. This policy’s utilization criteria are aligned with FDA labeling (including age and diagnostic requirements), emphasize provider‑administered injections for the medical benefit, and require prescriptions from specified specialty prescribers and adherence to FDA dosing guidance.

Term	Definition
Self-administration not appropriate	Physician-documented reasons such as history of anaphylaxis; new to therapy requiring initial supervised doses (authorization for three doses); prior therapy interrupted ≥ 6 months requiring re‑initiation under provider guidance (authorization for three doses); patient or caregiver unable to recognize or treat anaphylaxis appropriately; patient or caregiver unable to perform subcutaneous injections with proper technique or adhere to dosing regimen; or location/circumstances for self-administration inadequate for potential treatment of anaphylaxis.
Nasal Polyp Score (NPS)	Endoscopic score range 0–4 per nostril (total 0–8); per-nostril scores: 0 = no polyps; 1 = small polyps in middle meatus not reaching below inferior border of middle turbinate; 2 = polyps reaching below lower border of middle turbinate; 3 = large polyps reaching lower border of inferior turbinate or medial to middle turbinate; 4 = large polyps causing complete obstruction of the inferior nasal cavity.
Type I allergic reactions	Examples include nausea, vomiting, cramping, diarrhea, flushing, pruritus, urticaria, swelling of the lips/face/throat, wheezing, lightheadedness, and syncope.

Revision History

2024-08-01material_change_addedLatest

Added 'emergency treatment of allergic reactions, including anaphylaxis' to the list of unproven and not medically necessary indications.

2024-08-01material_change_removedLatest

Removed 'peanut allergy' from the list of unproven and not medically necessary indications.

2024-08-01material_change_added

Policy Summary

PayerUnitedHealthcare

PolicyXolair (omalizumab) provider-administered injections

Policy CodePolicy CS2024D0033AC

Change TypeAdded IgE-mediated food allergy; other content revised/removed

Effective DateAug 1, 2024

Next Review Date

On This Page

Documentation Required

Document prior therapy trials and response

Document prior therapy trials and clinical response before requesting Xolair for the relevant indication.

Chronic urticaria: documentation of at least a 2-week trial of, or history of intolerance/contraindication to, two H1-antihistamines (or combination antihistamine regimens per policy) and continued symptoms despite therapy.
Nasal polyps: documentation of prior endoscopic sinus surgery or systemic corticosteroid course, or failure/inadequate response to intranasal corticosteroids plus other appropriate therapies, as applicable.

Documentation Required

Physician specialty requirement

Prescribing clinician specialty must align with the indication for Xolair administration and is required on requests.

Asthma: prescriber must be an allergist/immunologist or pulmonologist.
Chronic urticaria: prescriber must be an allergist/immunologist or dermatologist.
Nasal polyps: prescriber must be an allergist/immunologist, otolaryngologist (ENT), or pulmonologist.
IgE‑mediated food allergy: prescriber must be an allergist/immunologist.

Denial Risk

Concurrent biologic therapy exclusion

Concurrent use of other biologic therapies targeting overlapping pathways may lead to claim denial; confirm patient is not receiving excluded agents.

Claims may be denied if the patient is receiving anti-IL-4 (e.g., dupilumab), anti-IL-5 (e.g., mepolizumab, reslizumab, benralizumab), or TSLP inhibitors (e.g., tezepelumab) concurrently with Xolair.

Documentation Required

Self-administration attestation and supporting documentation

When provider administration is requested because self-administration is unsuitable, include a physician attestation describing the reason. Some situations permit short supervised dosing authorizations (three doses) prior to transition to self-administration.

Acceptable attestation reasons include: history of anaphylaxis to Xolair or other agents (e.g., foods, drugs, biologics).
Patient is new to Xolair and requires initial doses administered under supervision until no hypersensitivity reactions occur (when applicable, authorization will be for three supervised doses).
Previous Xolair therapy was interrupted ≥ 6 months and re-initiation requires supervised doses (when applicable, authorization will be for three supervised doses).
Patient or caregiver is unable to recognize or appropriately treat anaphylaxis.
Patient or caregiver is unable to perform subcutaneous injections with proper technique or adhere to dosing.
Location/circumstances for self-administration are inadequate to manage potential anaphylaxis.

Prior Authorization

Prior authorization required for IgE-mediated food allergy (provider administration)

Prior authorization is required for provider-administered Xolair when used for IgE‑mediated food allergy. Requests must document specialty, safety measures, diagnostic confirmation, dosing per FDA, and exclude concomitant biologics. Initial approvals are limited to 12 months.

Prescriber must be an allergist/immunologist.
Documentation that the patient has access to and carries epinephrine for anaphylaxis.
Diagnostic confirmation per food: compatible clinical history plus confirmatory testing (e.g., positive SPT, serum specific IgE, and/or supervised OFC where indicated).
Dosing must follow current FDA‑approved labeling for omalizumab when used for food allergy.
Initial authorization will be for no more than 12 months.
Patient must not be receiving concomitant biologic therapies that are excluded (e.g., anti-IL-4, anti-IL-5, TSLP inhibitors).